Pluristem Submits FDA Orphan Drug Application for Preeclampsia

[GlobeNewswire] – HAIFA, Israel — Pluristem Therapeutics, Inc. , a leading developer of placenta-based cell therapies, today announced it is submitting its application to the United Stated Food and Drug Administration … more

View todays social media effects on PSTI

View the latest stocks trending across Twitter. Click to view dashboard

See who Pluristem is hiring next, click here to view